Supporting the Full ADC Discovery Process
The discovery and development process for Antibody Drug Conjugates (ADCs), or immunoconjugates, is complex and poses significant challenges. Genedata Biologics® supports the full ADC discovery process from antibody screening and engineering, to antibody expression, purification, drug conjugation, and reporting of ADC-specific analytics (e.g., DAR, drug distribution, homogeneity).
ADC Design, Engineering & Testing
Genedata Biologics enables the registration and tracking of large panels of ADC candidates and manages all linker and payload information (e.g., cytotoxic small molecules). By incorporating results from analytics and functional assays in one integrated platform, Genedata Biologics substantially increases throughput and efficiency in ADC discovery.
Genedata Biologics is a key component of our growth plans in the immuno-oncology and next-generation ADC space.
Thomas Sandal, Ph.D.
Vice President, R&D
Customer Stories
Scalable Backbone System Supports ADC Discovery
"Genedata Biologics is a key component of our growth plans in the immuno-oncology and next-generation ADC space. Thanks to its flexible architecture, Genedata Biologics can truly support our entire discovery process—right through from the immunization of transgenic mice, to lead selection, molecular modification and final candidate assessments.”
Design, Production, and Analytics of ADCs
Genedata Biologics enables the registration and tracking of large panels of ADC candidates, and integrates results from analytics and functional assays in one integrated system, thereby substantially increasing throughput and efficiency of the ADC discovery process.